Molecular pathology of non-small cell lung cancer: a practical guide.

The traditional distinction between small cell lung cancer and non-small cell lung cancer (NSCLC) is no longer sufficient for treatment planning. It is advised to handle small diagnostic specimens prudently because they are often the only specimen available for molecular analysis. Pathologists are experiencing pressure to subclassify lung carcinoma based on extremely small tumor samples, because NSCLC tumor subtyping is now essential to determine molecular testing strategies. Evaluation for EGFR mutations and ALK rearrangements are now considered to be the standard of care in advanced-stage pulmonary adenocarcinomas. Immunohistochemical stains can aid in subclassifying NSCLC, but performing these ancillary studies can significantly reduce the quantity of tissue available for molecular tests, requiring careful balancing of these 2 needs. The pathologist plays a pivotal role in facilitating clear and timely communication between the clinical oncology care team and the molecular laboratory to ensure that the appropriate tests are ordered and optimal material is submitted for testing.

[1]  Yi-long Wu,et al.  Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression , 2010, Molecular Cancer.

[2]  G. Shapiro,et al.  Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. , 2010, Current opinion in investigational drugs.

[3]  Yuki Togashi,et al.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. , 2008, Cancer research.

[4]  D. Wigle,et al.  Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors , 2009, Clinical Cancer Research.

[5]  D Neil Watkins,et al.  Novel therapeutic targets in non-small cell lung cancer. , 2013, Current opinion in pharmacology.

[6]  Armando Santoro,et al.  A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. , 2009, American journal of respiratory and critical care medicine.

[7]  W. Franklin,et al.  Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment , 2010, Clinical Cancer Research.

[8]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[9]  M. Ladanyi,et al.  Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. , 2010, The Journal of molecular diagnostics : JMD.

[10]  H. Sasaki,et al.  PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.

[11]  L. Layfield,et al.  Respiratory cytology in the era of molecular diagnostics: A review , 2012, Diagnostic cytopathology.

[12]  A. Iafrate,et al.  A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.

[13]  T. Mitsudomi,et al.  Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer? , 2011, The Lancet. Oncology.

[14]  K. Nagai,et al.  Prognostic impact of histology on early-stage non-small cell lung cancer. , 2011, Chest.

[15]  Jeffrey W. Clark,et al.  Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  William Pao,et al.  Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation , 2010, Clinical Cancer Research.

[17]  P. Jänne,et al.  The biology and treatment of EML4-ALK non-small cell lung cancer. , 2010, European journal of cancer.

[18]  Renato Martins,et al.  Non-small cell lung cancer. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  A. Shaw,et al.  Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) , 2012 .

[20]  A. Nicholson,et al.  ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. , 2012, Lung cancer.

[21]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[22]  P. Jänne,et al.  Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). , 2012 .

[23]  F. de Marinis,et al.  Identification of EGFR mutations in lung sarcomatoid carcinoma , 2011, International journal of cancer.

[24]  Naobumi Tochigi,et al.  Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. , 2011, American journal of clinical pathology.

[25]  E. Brambilla,et al.  The evolving role of histology in the management of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Aló,et al.  Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. , 2010, Anticancer research.

[27]  R. Dziadziuszko,et al.  Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer , 2011, British Journal of Cancer.

[28]  S. Ramalingam,et al.  The Biology and Clinical Features of Non–small Cell Lung Cancers with EML4-ALK Translocation , 2012, Current Oncology Reports.

[29]  M. Fukuoka,et al.  Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer , 2008, Cancer science.

[30]  Y. Ishikawa,et al.  A mouse model for EML4-ALK-positive lung cancer , 2008, Proceedings of the National Academy of Sciences.

[31]  P Baas,et al.  Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  P. Jänne,et al.  Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. , 2006, The Journal of clinical investigation.

[33]  A. Shaw,et al.  Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). , 2012 .

[34]  F. Cappuzzo,et al.  Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. , 2011, Lung cancer.

[35]  An-Ting T. Lu,et al.  Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. , 2011, Clinical colorectal cancer.

[36]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[37]  Giancarlo Troncone,et al.  Cytology‐based gene mutation tests to predict response to anti‐epidermal growth factor receptor therapy: A review , 2011, Diagnostic cytopathology.

[38]  Jie Gao,et al.  Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas , 2010, BMC Cancer.

[39]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[40]  E. A. Nelson,et al.  A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. , 2006, Health technology assessment.

[41]  M. Ladanyi,et al.  Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[43]  M. Ladanyi,et al.  Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[44]  Y. Bang,et al.  Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  M. Gaub,et al.  MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  C. Isella,et al.  Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations , 2011, Clinical Cancer Research.

[47]  Cindy Tran,et al.  EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology , 2011, Clinical Cancer Research.

[48]  B. Betz,et al.  The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. , 2011, American journal of clinical pathology.

[49]  David N Louis,et al.  Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine , 2010, EMBO molecular medicine.

[50]  S. Paik,et al.  A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes , 2010, BMC Cancer.

[51]  A. Iafrate,et al.  Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.

[52]  S. Novello,et al.  Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer , 2012, Drugs.

[53]  S. Ou.  Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond , 2011, Drug design, development and therapy.

[54]  Gayatry Mohapatra,et al.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR , 2005, Nature Genetics.

[55]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  N. Girard,et al.  New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.

[57]  I. Wistuba,et al.  Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[58]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[59]  M. Antoine,et al.  Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. , 2010, Lung cancer.

[60]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[61]  Y. Maehara,et al.  Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer , 2010, Clinical Cancer Research.

[62]  G. Troncone,et al.  EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study , 2011, Journal of Clinical Pathology.

[63]  S. Kobayashi,et al.  Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[64]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[65]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[66]  K. Kiura,et al.  Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. , 2011, Lung cancer.

[67]  R. Salgia,et al.  MET as a target for treatment of chest tumors. , 2009, Lung cancer.

[68]  P. Jänne,et al.  Crizotinib for ALK-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target , 2012, Clinical Cancer Research.

[69]  Sanjay Mukhopadhyay,et al.  Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy Specimens: Utility of an Immunohistochemical Panel Containing TTF-1, Napsin A, p63, and CK5/6 , 2011, The American journal of surgical pathology.

[70]  T. Goya,et al.  Abnormalities of epidermal growth factor receptor in lung squamous‐cell carcinomas, adenosquamous carcinomas, and large‐cell carcinomas , 2007, Cancer.

[71]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[72]  M. Tsao,et al.  Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors , 2009, Oncogene.

[73]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[74]  L. Landi,et al.  Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer , 2012, Drugs.

[75]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[76]  S. Thibodeau,et al.  Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study , 2008, Modern Pathology.

[77]  S. Fujita,et al.  Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation. , 2012, Internal medicine.

[78]  S. Park,et al.  Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung , 2009, Journal of Korean medical science.

[79]  G. Troncone,et al.  KRAS mutation analysis on cytological specimens of metastatic colo‐rectal cancer , 2010, Diagnostic cytopathology.

[80]  R. Pirker,et al.  Monoclonal antibodies against EGFR in non-small cell lung cancer. , 2011, Critical reviews in oncology/hematology.

[81]  M. Ladanyi,et al.  Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. , 2011, The Journal of thoracic and cardiovascular surgery.

[82]  S. Finkelstein,et al.  Microdissection techniques for molecular testing in surgical pathology. , 2004, Archives of pathology & laboratory medicine.

[83]  A. Italiano,et al.  EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti‐EGFR treatment of a rare lung malignancy , 2009, International journal of cancer.

[84]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[85]  P. Meltzer,et al.  Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. , 2010, The Journal of molecular diagnostics : JMD.

[86]  D. Jablons,et al.  Lung cancer therapeutics that target signaling pathways: an update , 2010, Expert review of respiratory medicine.

[87]  D. Sidransky,et al.  Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.

[88]  G. Giaccone,et al.  Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors , 2012, Current opinion in oncology.

[89]  Ron Brown,et al.  The Henry Ford production system: LEAN process redesign improves service in the molecular diagnostic laboratory: a paper from the 2008 William Beaumont hospital symposium on molecular pathology. , 2009, The Journal of molecular diagnostics : JMD.

[90]  S. Novello,et al.  Lung cancer in never smokers: a different disease , 2014, Current Respiratory Care Reports.

[91]  C. Langer.  Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. , 2012, Critical reviews in oncology/hematology.

[92]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[93]  S. Anderson.  Laboratory methods for KRAS mutation analysis , 2011, Expert review of molecular diagnostics.

[94]  D. Costa,et al.  Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities , 2011, Therapeutic advances in medical oncology.

[95]  Ravi Salgia,et al.  MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. , 2009, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[96]  G. Giaccone,et al.  American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  M. Tsao,et al.  Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. , 2012, Lung cancer.

[98]  N. Waugh,et al.  The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. , 2006, Health technology assessment.

[99]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[100]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[101]  Renato Martins,et al.  Non-small cell lung cancer. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[102]  A. Atherly,et al.  The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers , 2012, British Journal of Cancer.

[103]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[104]  Qinghua Zhou,et al.  Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib , 2010, Cancer biology & therapy.

[105]  L. Tanoue.  Use of Epidermal Growth Factor Receptor/Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Mutation Testing to Define Clonal Relationships Among Multiple Lung Adenocarcinomas: Comparison With Clinical Guidelines , 2011 .

[106]  A. Sihoe,et al.  The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS , 2009, Cancer.

[107]  W. Travis,et al.  Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. , 2011, Seminars in respiratory and critical care medicine.

[108]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[109]  William Pao,et al.  ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors , 2011, Clinical Cancer Research.

[110]  Gang Chen,et al.  EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. , 2011, Lung cancer.

[111]  Y. Mitani,et al.  Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. , 2011, Oncology reports.

[112]  P. Jänne,et al.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[113]  A. Gazdar.  Personalized medicine and inhibition of EGFR signaling in lung cancer. , 2009, The New England journal of medicine.

[114]  B. Jeremic,et al.  Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy , 2011, Cancer.

[115]  M. Mino‐Kenudson,et al.  Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. , 2011, Archives of pathology & laboratory medicine.

[116]  A. Sepulveda,et al.  Evaluation of EGFR mutation status in cytology specimens: An institutional experience , 2013, Diagnostic cytopathology.

[117]  J. Koo,et al.  EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. , 2011, Clinical lung cancer.

[118]  Y. Yatabe,et al.  Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer , 2010, Clinical Cancer Research.

[119]  E. Zwarthoff,et al.  Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes , 2010, PloS one.

[120]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  Jeffrey W. Clark,et al.  Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. , 2012 .

[122]  L. Benesova,et al.  Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. , 2010, Anticancer research.

[123]  W. Lam,et al.  MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors , 2009, International journal of cancer.

[124]  D. Lopez-Terrada,et al.  Molecular testing of solid tumors. , 2011, Archives of pathology & laboratory medicine.

[125]  D. Berry,et al.  Benefits and harms of CT screening for lung cancer: a systematic review. , 2012, JAMA.

[126]  S. Monaco,et al.  A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. , 2010, Human pathology.

[127]  Douglas C McCrory,et al.  Screening for lung cancer: a review of the current literature. , 2003, Chest.

[128]  G. Rossi,et al.  EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. , 2009, American journal of clinical pathology.

[129]  M. Ladanyi,et al.  Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations , 2012, Clinical Cancer Research.

[130]  E. Stathopoulos,et al.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC , 2008, British Journal of Cancer.

[131]  K. Müller,et al.  HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. , 2005, Lung cancer.

[132]  L. Bubendorf,et al.  The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. , 2012, Lung cancer.

[133]  M. Roizen.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[134]  L. Voltolini,et al.  Impact of Size, Histology, and Gender on Stage IA Non-Small Cell Lung Cancer , 2004, Asian cardiovascular & thoracic annals.

[135]  William Pao,et al.  Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[136]  Gregg Staerkel,et al.  EGFR and KRAS mutations in lung carcinoma , 2011, Cancer cytopathology.

[137]  A. Tsao,et al.  ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .

[138]  S. Pullamsetti,et al.  Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer , 2011, Expert opinion on investigational drugs.

[139]  S. Dacic,et al.  Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas , 2010, Modern Pathology.

[140]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[141]  C. Powell,et al.  Molecular Testing in Lung Cancer: The Time Is Now , 2010, Current oncology reports.

[142]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  P. Jänne.  Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. , 2008, Lung cancer.

[144]  A. Yoshizawa,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.

[145]  W. Pao,et al.  KRAS mutations in non-small cell lung cancer. , 2009, Proceedings of the American Thoracic Society.

[146]  M. L. R. D. Christenson,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2012 .

[147]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[148]  S. Raab.  Optimal Immunohistochemical Markers for Distinguishing Lung Adenocarcinomas From Squamous Cell Carcinomas in Small Tumor Samples , 2012 .

[149]  H. Kosmehl,et al.  Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas , 2009, British Journal of Cancer.

[150]  H. Choy,et al.  Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. , 2012, International journal of radiation oncology, biology, physics.

[151]  E. Ma,et al.  Synchronous primary lung cancer and epidermal growth factor receptor mutation. , 2010, The Annals of thoracic surgery.

[152]  Hoguen Kim,et al.  Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung , 2007, Cancer.

[153]  D. Aisner,et al.  The role of cytology specimens in molecular testing of solid tumors: Techniques, limitations, and opportunities , 2012, Diagnostic cytopathology.

[154]  A. Warth,et al.  Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy , 2011, European Respiratory Journal.

[155]  Miguel Angel Molina,et al.  Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer , 2010, Journal of Translational Medicine.

[156]  F. Cappuzzo,et al.  Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[157]  W. Franklin,et al.  Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[158]  M. Ladanyi,et al.  Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method , 2007, Clinical Cancer Research.

[159]  W. Pao,et al.  Chipping away at the lung cancer genome , 2012, Nature Medicine.

[160]  C. Jumper,et al.  Prognosis of metastatic carcinoma of the lung in the bevacizumab era: comparison between the major histologic types of lung cancer. , 2012, The Journal of surgical research.

[161]  V. Rusch,et al.  Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[162]  J. Christensen,et al.  Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.

[163]  Jeffrey W. Clark,et al.  Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[164]  R. A. Hubbard,et al.  Comparative evaluation of three JAK2V617F mutation detection methods. , 2007, American journal of clinical pathology.

[165]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[166]  Kazutaka Nakashima,et al.  Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[167]  M. Ladanyi,et al.  Integration of Molecular Profiling into the Lung Cancer Clinic , 2009, Clinical Cancer Research.

[168]  H. Osada,et al.  EGFR point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplification , 2006, Cancer science.

[169]  M. Tsao,et al.  A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[170]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[171]  Atul C Mehta,et al.  Evidence-Based Clinical Practice Guidelines Initial Diagnosis of Lung Cancer : ACCP , 2007 .

[172]  T. Kohno,et al.  Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas , 2011, The American journal of surgical pathology.

[173]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  M. Socinski,et al.  Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  Michael Thomas,et al.  Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[176]  Nobuyoshi Shimizu,et al.  Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. , 2006, Cancer research.

[177]  W. Travis,et al.  Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[178]  D. Costa,et al.  ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[179]  E. Giovannetti,et al.  Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[180]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[181]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[182]  A. Rossi,et al.  Pemetrexed in advanced non-small cell lung cancer , 2011, Expert opinion on drug safety.

[183]  K. Matsuo,et al.  Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[185]  I. Okamoto,et al.  MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[186]  D. Camidge,et al.  The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence , 2011 .

[187]  Laura J. Winter,et al.  Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. , 2011, The Journal of molecular diagnostics : JMD.

[188]  G. Giaccone,et al.  Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[189]  M. Ladanyi,et al.  New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer , 2011, Clinical Cancer Research.

[190]  A. Jemal,et al.  Changes in smoking prevalence among U.S. adults by state and region: Estimates from the Tobacco Use Supplement to the Current Population Survey, 1992-2007 , 2011, BMC public health.

[191]  Kenji Suzuki,et al.  Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. , 2012, Lung cancer.

[192]  J. Minna,et al.  Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. , 2005, Human pathology.

[193]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[194]  G. da Cunha Santos,et al.  EGFR gene status in cytological samples of nonsmall cell lung carcinoma , 2011, Cancer cytopathology.

[195]  M. Ladanyi,et al.  ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[196]  H. Lee,et al.  High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[197]  M. Ladanyi,et al.  Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.

[198]  Y. Yatabe,et al.  Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. , 2011, Lung cancer.

[199]  A. Gemma,et al.  Frequency of and variables associated with the EGFR mutation and its subtypes , 2010, International journal of cancer.

[200]  M. Tsao,et al.  EGFR mutations and lung cancer. , 2011, Annual review of pathology.

[201]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[202]  J. Soh,et al.  The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer , 2007, Clinical Cancer Research.

[203]  R. Wilson,et al.  Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[204]  T. Ohira,et al.  Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.